Product Highlight - Breztri Aerosphere

Powerful protection for symptomatic patients with COPD at risk of exacerbations^1,2
• Breztri significantly reduces the rate of moderate or severe exacerbations versus both LAMA/LABA and ICS/LABA²
• Breztri showed lung function improvement over 24 weeks versus LAMA/LABA and ICS/LABA¹
• Optimal particle size enables delivery to the large and small airways³
• Fast onset of action in 5 minutes¹
• Can be used together with spacer⁴

References:
1. Ferguson GT, et al. Lancet Respir Med. 2018 Oct;6(10):747-758.
2. Rabe KF, et al. N Engl J Med. 2020; 383:35-48.
3. Usmani O, et al. Int J Chron Obstruct Pulmon Dis. 2021; 16:113-124.
4. Breztri Aerosphere HK Prescribing Information. Oct 2022.

For healthcare professionals only.
Please visit contactazmedical.astrazeneca.com for (1) enquiring Medical Information (MI), (2) reporting Individual Case Safety Report (ICSR) and/or (3) reporting Product Quality Complaint (PQC) to AstraZeneca Hong Kong Limited.

HK-9616 08/11/2023